Form 4: Blueprint Medicines Officer Disposes of Shares Following Sanofi Merger Completion

Blueprint Medicines Corp's Chief People Officer, Debra Durso-Bumpus, disposed of all beneficial ownership in common stock and stock options following the completion of Sanofi's acquisition of the company on July 17, 2025.

Summary

• Blueprint Medicines Corp (BPMC) was acquired by SANOFI through its subsidiary, Rothko Merger Sub, Inc., via a tender offer.
• The acquisition was completed on July 17, 2025, at which point Rothko Merger Sub, Inc. merged with and into Blueprint Medicines Corp, with BPMC surviving as an indirect wholly owned subsidiary of SANOFI.
• Shareholders received $129.00 per share in cash, plus one contractual contingent value right (CVR) per share, representing the right to receive contingent payments upon the achievement of certain milestones.
• Debra Durso-Bumpus, Chief People Officer, disposed of 21,353 shares of common stock acquired from performance-based vesting conditions (PSUs) and 70,959 shares of common stock from PSUs.
• An additional 51,103 shares of common stock from restricted stock units (RSUs) and 19,856 shares from RSUs were disposed of.
• All common stock held directly by the reporting person, totaling 19,856 shares, was tendered in exchange for the offer consideration.
• All outstanding stock options, whether vested or unvested, became fully vested and were cancelled, converting into the right to receive the cash offer price (less exercise price) and one CVR per share.
• Fifty percent of PSUs, RSUs, and stock options issued in calendar year 2025 were converted into cash-based awards subject to continued vesting based on the Cash Offer Price, plus one CVR for each underlying share.
• Following these transactions, Debra Durso-Bumpus holds 0 shares of common stock and 0 derivative securities beneficially owned.

Sentiment

Score: 8

Explanation: The document reports the successful completion of a major acquisition, which is generally positive for the target company's shareholders who received a premium. The insider's transactions are a direct, expected outcome of this positive event.

Positives

• The merger successfully completed, providing Blueprint Medicines shareholders with a definitive exit at a premium.
• Shareholders received a cash payment of $129.00 per share, along with a Contingent Value Right (CVR) which offers potential future payments based on milestone achievements.
• All outstanding stock options and equity awards (PSUs, RSUs) held by the reporting person became fully vested and were converted into the merger consideration, providing liquidity for these holdings.

Negatives

• Blueprint Medicines Corp ceased to be an independent publicly traded entity, becoming an indirect wholly owned subsidiary of Sanofi.
• The reporting person, Debra Durso-Bumpus, no longer holds any direct beneficial ownership in Blueprint Medicines Corp common stock or derivative securities.

Risks

• No new risks are identified in this post-merger filing, as it reports on the completion of a transaction.

Future Outlook

Blueprint Medicines Corp is now an indirect wholly owned subsidiary of Sanofi. The document does not provide forward-looking statements for Blueprint Medicines as an independent entity, as its operations are now integrated under Sanofi.

Industry Context

This acquisition reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies like Sanofi seek to expand their pipelines and market presence by acquiring innovative smaller biotech firms. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards related to clinical or regulatory milestones.

Comparison to Industry Standards

• The acquisition price of $129.00 per share plus a CVR represents a significant premium, which is typical for strategic acquisitions of biotech companies with promising assets.
• The inclusion of a CVR is a standard practice in biotech M&A, aligning the interests of the acquirer and the target's former shareholders regarding the future success of specific pipeline assets.
• The immediate vesting and conversion of equity awards for executives upon merger completion is a common provision in change-of-control clauses within executive compensation agreements across the industry.

Stakeholder Impact

• Shareholders: Received $129.00 cash per share plus one CVR, realizing value from their investment.
• Employees (including reporting person): Equity awards were converted into cash and CVRs, with some 2025 awards converting to cash-based awards subject to continued vesting, providing financial benefit and continuity for some.

Next Steps

• Blueprint Medicines Corp will operate as an indirect wholly owned subsidiary of Sanofi.
• Former Blueprint Medicines shareholders will receive the cash consideration and hold CVRs, which may lead to future payments upon milestone achievement.

Key Dates

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Tender Offer, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Performance Share Units, Contingent Value Right, CVR